Mantis Biotech Pioneers Digital Twins to Solve Healthcare's Data Shortage

Got story updates? Submit your updates here. ›

Mantis Biotech, a New York-based biotech company, is pioneering the use of digital twin technology to address a critical challenge in healthcare - the scarcity of reliable medical data. By integrating diverse data sources, Mantis is able to create predictive models of virtual patient populations, enabling faster, more accurate medical research and drug development.

Why it matters

The lack of comprehensive, high-quality medical data has long hindered progress in healthcare, slowing the development of new treatments and therapies. Mantis Biotech's digital twin technology offers a novel solution, allowing researchers to simulate clinical trials and test new drugs on virtual patient populations, accelerating the pace of innovation in the industry.

The details

Mantis Biotech's digital twin platform combines data from electronic health records, genomic sequencing, wearable devices, and other sources to create detailed, individualized virtual models of patients. These digital twins can then be used to simulate clinical trials, test new treatments, and predict patient responses, providing researchers with a powerful tool to drive medical breakthroughs.

• Mantis Biotech was founded in 2020 in New York City.
• The company's digital twin technology was first unveiled in 2024.
• Mantis Biotech announced the successful application of its digital twin platform in a major clinical trial in March 2026.

What’s next

Mantis Biotech plans to continue expanding its digital twin platform, integrating more data sources and refining its predictive models to support a growing number of clinical trials and drug development programs.